Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., No. 17-2078 (Fed. Cir. Sept. 10, 2018)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before us are patents that claim the administration of a medication containing the active ingredient 4- aminopyridine (4 -AP) to improve walking in individuals with multiple sclerosis. Acorda Therapeutics, Inc., holds New Drug Application No. 022250 , approved by the U.S. Food and Drug Administration (FDA) . Pursuant to that approval, Acorda market s, under the name “Ampyra®,” 10 m illigram 4- AP sustained-release tablets for twice- daily oral administration .